Predictors of low-level viremia in chronic hepatitis B and the efficacy of pegylated interferon-alpha: a real-world study
Open Access
- 14 November 2025
- journal article
- research article
- Published by Springer Nature in Virology Journal
- Vol. 22 (1) , 375
Abstract
Low-level viremia (LLV) is closely associated with the prognosis of patients with chronic hepatitis B (CHB), it can increase the incidence of cirrhosis and hepatocellular carcinoma. Our research aims to explore how to identify LLV early and implement effective therapeutic intervention. This retrospective study included 720 patients who were either treatment-naive or had not received treatment within the past 5 years. After 48 weeks follow-up, they were categorized into either the complete virological response (CVR) or LLV. Independent risk factors associated with LLV were screened by LASSO regression analysis and a prediction model incorporating these factors was developed. Furthermore, among patients who developed LLV, we compared the therapeutic efficacy of nucleos(t)ide analogue (NAs) monotherapy and pegylated interferon alpha (IFNα)-based combination therapy. Firstly, four independent risk variables were found to be connected to the incidence of LLV, including age, baseline HBV DNA level, baseline HBsAg level, and baseline HBeAg status. The model showed AUCs of 0.861 (training) and 0.799 (validation), with good calibration. Secondly, between IFNα-based combination therapy and NAs monotherapy group, HBV DNA clearance rates showed no difference at week 24 but significant divergence at week 48 (p = 0.684 and p = 0.001). HBsAg decline rates (in patients with baseline HBsAg ≥ 1500 IU/mL) differed significantly at both 24/48 weeks (p < 0.001). Throughout the 48-week follow-up, the cumulative rates of HBV DNA clearance (p < 0.001), HBsAg loss (p < 0.001), HBeAg loss (p = 0.008), and HBeAg seroconversion (p = 0.001) were all significantly higher in the combination therapy group, though the cumulative HBsAg seroconversion rate was not (p = 0.535). Furthermore, stratified analysis confirmed the superior efficacy of IFNα-based combination therapy across key subgroups. It outperformed NAs monotherapy both in patients with HBsAg ≥ 1500 IU/mL (24w: p = 0.031; 48w: p = 0.002) and in those with HBV DNA < 500 IU/mL (24w: p = 0.01; 48w: p < 0.001). Age, baseline HBV DNA level, HBsAg level, and HBeAg status were independently associated with the prevalence of LLV independently. Compared to NAs monotherapy, IFNα-based combination therapy in LLV patients demonstrated significantly higher rates of CVR, HBsAg decline, HBsAg loss/seroconversion, and HBeAg loss.Keywords
This publication has 48 references indexed in Scilit:
- Long-term effects of peginterferon-based therapy versus nucleos(t)ide analogue monotherapy in non-cirrhotic HBeAg-positive chronic hepatitis B patientsAntiviral Research, 2025
- Interim analysis of the PARADISE study: Benefits of add-on peginterferon-α in NA-treated patients with CHBAntiviral Research, 2024
- Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-α: a systematic review and meta-analysisHepatology International, 2024
- Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis BJournal of Hepatology, 2022
- How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?Journal of Hepatology, 2022
- Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During TherapyClinical Gastroenterology and Hepatology, 2020
- Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B GuidanceClinical Liver Disease, 2018
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infectionJournal of Hepatology, 2017
- Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis BJournal of Hepatology, 2017
- Low‐level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatmentHepatology, 2016